medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 2

<< Back

Ann Hepatol 2014; 13 (2)

SALLuting a new biomarker in hepatocellular carcinoma

Inghilesi AL, Marra F

Language: English
References: 21
Page: 305-307
PDF size: 67.47 Kb.


Text Extraction

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer worldwide and the third most frequent cause of cancer-related death, with increasing incidence in traditionally low-frequency regions like the United States and Northern Europe. A relevant proportion of patients with HCC present with advanced disease, and the only approved therapy in this subgroup is the multi-kinase inhibitor sorafenib, approved in 2008. The lack of novel and/or second- line therapies, and the limited survival benefit provided by sorafenib underscore the urgent need for novel treatment options in advanced HCC. This goal may be more easily achieved with a better understanding of the molecular pathogenesis of this cancer, which is characterized by a marked heterogeneity. Unfortunately, the molecular mechanisms leading to HCC diversity and to its variable prognosis are still far to be defined.


REFERENCES

  1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.

  2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.

  3. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013; 368: 2266-76.

  4. Elling U, Klasen C, Eisenberger T, Anlag K, Treier M. Murine inner cell mass-derived lineages depend on Sall4 function. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 16319-24.

  5. Yang J, Gao C, Chai L, Ma Y. A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PloS one 2010; 5: e10766.

  6. Rao S, Zhen S, Roumiantsev S, McDonald LT, Yuan GC, Orkin SH. Differential roles of Sall4 isoforms in embryonic stem cell pluripotency. Molecular and Cellular Biology 2010; 30: 5364-80.

  7. Kohlhase J, Chitayat D, Kotzot D, Ceylaner S, Froster UG, Fuchs S, et al. SALL4 mutations in Okihiro syndrome (Duane- radial ray syndrome), acro-renal-ocular syndrome, and related disorders. Hum Mutat 2005; 26: 176-83.

  8. Oikawa T, Kamiya A, Kakinuma S, Zeniya M, Nishinakamura R, Tajiri H, et al. Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. Gastroenterology 2009; 136: 1000-11.

  9. Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM, et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 2006; 108: 2726-35.

  10. Cui W, Kong NR, Ma Y, Amin HM, Lai R, Chai L. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2006;19: 1585-92.

  11. Kobayashi D, Kuribayshi K, Tanaka M, Watanabe N. SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer. International Journal of Oncology 2011; 38: 933-9.

  12. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-6.

  13. Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology 2012; 55: 298-306.

  14. Gao C, Dimitrov T, Yong KJ, Tatetsu H, Jeong HW, Luo HR, et al. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood 2013; 121: 1413-21.

  15. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 2013; 57: 1469-83.

  16. Zeng SS, Yamashita T, Kondo M, Nio K, Hayashi T, Hara Y, et al. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol 2014; 60: 127-34.

  17. Moeini A, Cornella H, Villanueva A. Emerging Signaling Pathways in Hepatocellular Carcinoma. Liver Cancer 2012; 1: 83-93.

  18. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.

  19. Yong KJ, Chai L, Tenen DG. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 2013; 369: 1171-2.

  20. Panis C, Pizzatti L, Herrera AC, Cecchini R, Abdelhay E. Putative circulating markers of the early and advanced stages of breast cancer identified by high-resolution label- free proteomics. Cancer Lett 2013; 330: 57-66.

  21. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63.




2020     |     www.medigraphic.com